Abstract:Rationale: Cardiac fibrosis is a common feature in left ventricular remodeling that leads to heart failure, regardless of the cause. EphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression. Recently, EphrinB2 was reported to protect kidneys from injury-induced fibrogenesis. However, its role in cardiac fibrosis remains to be clarified.Objective: We sought to determine the role of EphrinB2 in cardiac fibrosis and the underlying mechanisms during the pathological remodeling process.Methods and Results: EphrinB2 was highly expressed in the myocardium of patients with advanced heart failure, as well as in mouse models of myocardial infarction and cardiac hypertrophy induced by angiotensin II infusion, which was accompanied by myofibroblast activation and collagen fiber deposition. In contrast, intramyocardial injection of lentiviruses carrying EphrinB2-shRNA ameliorated cardiac fibrosis and improved cardiac function in mouse model of myocardial infarction. Furthermore, in vitro studies in cultured cardiac fibroblasts demonstrated that EphrinB2 promoted the differentiation of cardiac fibroblasts into myofibroblasts in normoxic and hypoxic conditions. Mechanistically, the profibrotic effect of EphrinB2 on cardiac fibroblast was determined via activating the Stat3 (signal transducer and activator of transcription 3) and TGF-beta (transforming growth factor-beta)/Smad3 (mothers against decapentaplegic homolog 3) signaling. We further determined that EphrinB2 modulated the interaction between Stat3 and Smad3 and identified that the MAD homology 2 domain of Smad3 and the coil-coil domain and DNA-binding domain of Stat3 mediated the interaction.Conclusions: This study uncovered a previously unrecognized profibrotic role of EphrinB2 in cardiac fibrosis, which is achieved through the interaction of Stat3 with TGF-beta/Smad3 signaling, implying a promising therapeutic target in fibrotic diseases and heart failure.

Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis

Epigenetic signatures in cardiac fibrosis: Focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

Epigenetic Regulation in Fibrosis Progress.

Current concepts in the epigenetic regulation of cardiac fibrosis

Cardiac Fibrosis: New Insights into the Pathogenesis

Epigenetic Regulation in Myocardial Fibroblasts and Its Impact on Cardiovascular Diseases

Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis

The role and molecular mechanism of epigenetics in cardiac hypertrophy

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

Extracellular matrix remodeling and cardiac fibrosis

Epigenetics and Fibrosis

Epigenetics and expression of key genes associated with cardiac fibrosis: NLRP3, MMP2, MMP9, CCN2/CTGF and AGT

Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets.

Epigenetics As a Versatile Regulator of Fibrosis

Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles

Epigenetic Modifications in Fibrotic Diseases: Implications for Pathogenesis and Pharmacological Targets

Proteomic Insights into Cardiac Fibrosis: from Pathophysiological Mechanisms to Therapeutic Opportunities

Crosstalk between oxidative stress and epigenetic marks: New roles and therapeutic implications in cardiac fibrosis

The Function and Therapeutic Potential of lncRNAs in Cardiac Fibrosis